Hematologic Malignancies
Sussing Out a 2nd Cancer Signal for CAR-T Therapy
The FDA recently required a classwide boxed warning on all commercial CAR T-cell therapies after an investigation ...
JULY 1, 2024
Measurable Residual Disease Testing in the Community Oncology Setting
In the game of chess, anticipating the correct response to each of your opponent’s moves on the board can ...
FEBRUARY 7, 2024
Cancer Patients May Mount Weak Immune Response Against COVID Despite Vaccination
Vaccinated cancer patients may mount less robust humoral and/or cellular immune responses against SARS-CoV-2 ...
JUNE 30, 2023
Cell-Free DNA Test Detects Cancers Prior to Signs or Symptoms
A novel blood test appears to hold promise for detecting an array of cancers, such as hematologic malignancies and ...
NOVEMBER 7, 2022
Adults With Blood Cancers More Likely to Respond to Booster Rather Than Initial Dose of COVID-19 Vaccine
In a study published online in the journal Cancer (published online July 11, 2022), less than half of patients with ...
OCTOBER 10, 2022
Survey Highlights Concerning Lack of Availability of ATRA for APL
Only 42% of institutions that treat acute leukemia patients and 31% of hospitals overall in the United States have ...
FEBRUARY 18, 2022
In Cancer Patients, Tranexamic Acid Prophylaxis Does Not Reduce Bleeding Risk
Commonly used to reduce bleeding in patients with hematologic malignancies and severe thrombocytopenia, tranexamic ...
MARCH 22, 2021
FDA Approves Copiktra for Relapsed or Refractory CLL, SLL
Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of ...
SEPTEMBER 29, 2018
Obinutuzumab + CHOP Fails To Beat R-CHOP for DLBCL
Obinutuzumab failed to produce a PFS advantage over rituximab when both drugs were combined with the standard CHOP ...
FEBRUARY 15, 2017
Lenalidomide Maintenance May Extend PFS in CLL
Lenalidomide maintenance extended PFS after first-line therapy in high-risk CLL patients and after second-line ...
FEBRUARY 14, 2017
Shaji Kumar, MD, on Ventoclax Monotherapy for Multiple Myeloma
Dr. Kumar sat down with Clinical Oncology News to discuss his presentation, “Venetoclax Monotherapy for ...
FEBRUARY 7, 2017
ASH Report: Variations in AML Therapies Lead to Improved Outcomes
San Diego—The liposomal, fixed-dose combination of cytarabine and daunorubicin, known as CPX-351, improves ...
JANUARY 31, 2017
